IQVIA Biotech JAPAC

Welcome to IQVIA Biotech in Japan and Asia Pacific (JAPAC), the extension of IQVIA Biotech global, aimed at providing a custom-built delivery solution for emerging biopharma and biotech customers.

Contact US

Presence in JAPAC

With our regional headquarters in Singapore and offices in 15 countries, IQVIA Biotech provides technology-enabled services and solutions to accelerate clinical and commercial success for local and multinational emerging biopharma clients operating in Japan and Asia Pacific.

IQVIA's Experience

1,460+

studies run by IQVIA over the last five years across all therapeutic areas throughout JAPAC
IQVIA's Coverage

17,700+

sites initiated by IQVIA over the last five years throughout JAPAC
IQVIA's Coverage

162K+

IQVIA patients enrolled throughout JAPAC in all therapeutic areas in the last five years
Flexible solutions designed for Biotech Companies
On-Demand webinar
Global Strategies for Accelerating Time to Market for Emerging Biopharmas
Register now

JAPAC Insights and Resources

Emerging Biotech/Biopharma Trends to Watch For in 2022
Learn More
How to Manage Complexity in Cell and Gene Therapy Clinical Trials (JAPAC)
Emerging biopharma companies are at the forefront of advanced therapies that are bringing hope to millions. As the CAGT space continues to grow, there are unique opportunities and challenges.
Learn More
Innovative Designs in Early Phase Oncology Studies (JAPAC)
Embracing innovative designs in early phase oncology studies, a burgeoning development segment in Japan-Asia Pacific
Learn More
Early Clinical Development in Japan, It's Time to Take a Fresh Look
With improved infrastructure, as well as being the world's second largest market for branded therapies, emerging biopharma of all sizes should be looking to Japan for early clinical development
Learn More
The Nuances of Hematologic Oncology Clinical Trials (JAPAC)
Investigating candidate treatments for blood cancers in Japan-Asia Pacific
Learn More
Optimizing Immuno-oncology Trials: The JAPAC Advantage for Biotechs
Considerations for managing trial complexity in developing novel anti-cancer treatments in Japan-Asia Pacific
Learn More
China: An Early Opportunity for Emerging Biopharma
Positive forces in the China market make early market entry both attractive and achievable
Learn More
Australia: The Destination for Early Phase Trials
The Australian clinical research landscape is primed for early phase research development for emerging biopharma
Learn More
Partnering Solutions for Emerging Biopharma (JAPAC)
Alternative outsourcing strategies to improve probability of success in Japan-Asia Pacific
Learn More
Asset Valuation & Due Diligence
Understand and articulate the market value of your asset
Learn More
Launch Strategy & Planning
Establish a path to optimal product launch
Learn More
IQVIA Biotech Clinical Development
Learn More
View All

Email Us